Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.020
+0.020 (2.00%)
At close: Oct 9, 2026, 4:00 PM EDT
1.074
+0.054 (5.29%)
After-hours: Oct 9, 2026, 7:16 PM EDT
Pliant Therapeutics Employees
Pliant Therapeutics had 49 employees as of December 31, 2025. The number of employees decreased by 122 or -71.35% compared to the previous year. That makes Pliant Therapeutics the 35,052nd largest employer in the world and 4,696th in the United States.
Employees
49
Change (1Y)
-122
Growth (1Y)
-71.35%
Revenue / Employee
n/a
Profits / Employee
-$1,883,449
Market Cap
63.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 49 | -122 | -71.35% |
| Dec 31, 2024 | 171 | 13 | 8.23% |
| Sep 30, 2024 | 166 | 7 | 4.40% |
| Jun 30, 2024 | 166 | 11 | 7.10% |
| Mar 31, 2024 | 158 | 22 | 16.18% |
| Dec 31, 2023 | 158 | 34 | 27.42% |
| Sep 30, 2023 | 159 | 45 | 39.47% |
| Jun 30, 2023 | 155 | 45 | 40.91% |
| Mar 31, 2023 | 136 | 35 | 34.65% |
| Dec 31, 2022 | 124 | 33 | 36.26% |
| Sep 30, 2022 | 114 | 24 | 26.67% |
| Jun 30, 2022 | 110 | 20 | 22.22% |
| Mar 31, 2022 | 101 | 11 | 12.22% |
| Dec 31, 2021 | 91 | 13 | 16.67% |
| Sep 30, 2021 | 90 | 20 | 28.57% |
| Jun 30, 2021 | 90 | 23 | 34.33% |
| Mar 31, 2021 | 90 | 28 | 45.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Adicet Bio | 102 |
| Alps Group | 93 |
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Boundless Bio | 28 |
| iBio, Inc. | 23 |
| RenovoRx | 17 |
PLRX News
- 9 days ago - Pliant Therapeutics appoints David Raben as Chief Medical Officer - TheFly
- 9 days ago - Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095 - TheFly
- 7 weeks ago - Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - GlobeNewsWire
- 7 weeks ago - Pliant Therapeutics reports Q2 EPS (36c), consensus (34c) - TheFly
- 1 month ago - Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 1 month ago - Pliant Therapeutics Quarterly report: Q2 2026 - Filings
- 1 month ago - Pliant Therapeutics Earnings release: Q2 2026 - Filings